KalVista Pharmaceuticals, Inc. (KALV)
15.67
-0.39
(-2.43%)
USD |
NASDAQ |
Mar 03, 13:20
KalVista Pharmaceuticals Research and Development Expense (Annual) : 76.72M for April 30, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| BioCryst Pharmaceuticals, Inc. | 164.74M |
| Modular Medical, Inc. | 14.70M |
| Iovance Biotherapeutics, Inc. | 300.27M |
| Plus Therapeutics, Inc. | 10.58M |
| BioStem Technologies, Inc. | 1.911M |